Join
Live feed
·
PRReleasevia Quantisnow
Imunon Inc. logo

IMUNON Hosts R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer

ByQuantisnow·Wall Street's wire, on your screen.
IMNN· Imunon Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track IMNN (Imunon Inc.) and more on Quantisnow.